Genoptix Sets IPO Terms

Genoptix Inc., a Carlsbad, Calif.-based provider of personalized medicine services for management of hematolymphatic disorders, has set its IPO terms to five million common shares being offered at between $14 and $16 per share. It would have an initial market cap of nearly $250 million, were it to price at the high end of its range. Genoptix plans to trade on the Nasdaq under ticker symbol GXDX, with Lehman Brothers serving as lead underwriter. Genoptix has raised around $49 million in VC funding since 1999, from firms like Enterprise Partners, Chicago Growth Partners, William Blair Capital Partners, Alliance Technology Ventures, Tullis-Dickerson and Excelsior Venture Partners.